Teva Stands By Orange Book Listings As FTC Takes Further Action

Firm Responds To Reports Of FTC Investigation Over Inhaler Patents, After Refusal To Delist

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.